Which are the antibodies to watch in 2013?

mAbs

Volumn 5, Issue 1, 2013, Pages 1-4

  Reichert, Janice M ^a  

^a Landes Bioscience   (United States)

Author keywords

Cancer; Clinical studies; Monoclonal antibodies

Indexed keywords

ACTOXUMAB; ALIROCUMAB; AMG 145; BEZLOTOXUMAB; ELOTUZUMAB; EPRATUZUMAB; GANTENERUMAB; GEVOKIZUMAB; INOTUZUMAB OZOGAMICIN; ITOLIZUMAB; IXEKIZUMAB; LEBRIKIZUMAB; MEPOLIZUMAB; MK 3415A; MONOCLONAL ANTIBODY; NAPTUMOMAB ESTAFENATOX; NECITUMUMAB; NIVOLUMAB; OBINUTUZUMAB; OCRELIZUMAB; ONARTUZUMAB; RACOTUMOMAB; RAMUCIRUMAB; RESLIZUMAB; ROMOSOZUMAB; SARILUMAB; SECUKINUMAB; SIRUKUMAB; SOLANEZUMAB; TABALUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOLIZUMAB;

ACUTE CORONARY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ALZHEIMER DISEASE; ANKYLOSING SPONDYLITIS; ASTHMA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR RISK; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL CANCER; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MICE; NEOPLASMS;

EID: 84872858296     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22976     Document Type: Review

References (5)

1. Giugliano R.P., Desai NR, Kohli P, Rogers W.J., Somaratne R., Huang F, et al; for the LAPLACETIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; In press; PMID:23141813; http://dx.doi.org/10.1016/S0140-6736(12)61770-X
2. Koren MJ, Scott R, Kim J.B., Knusel B., Liu T, Lei L, et al Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholester-olaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; In press; PMID:23141812; http://dx.doi.org/10.1016/S0140-6736(12) 61771-1
3. Raal F, Scott R, Somaratne R., Bridges I, Li G, Wasserman S.M., et al Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation 2012; 126:2408-17; PMID:23129602; http://dx.doi.org/10.1161/CIRCULATIONAHA.112.144055
4. Dias CS, Shaywitz AJ, Wasserman S.M., Smith B P, Gao B, Stolman D.S., et al Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels: Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins. J Am Coll Cardiol 2012; 60:1888-98; PMID:23083772; http://dx.doi.org/10.1016/j.jacc. 2012.08.986
5. Hurvitz S, Dirix L, Kocsis J., Gianni L, Lu J, Vinholes J., et al Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). European Multidisciplinary Cancer Conference, Stockholm, Sweden, September 23-27, 2011; abstract 5001